Glutamate-based Therapies for Psychiatric Disorders
Both metabotropic and ionotropic glutamate receptors present attractive “druggable” targets in treating disorders of the central nervous system. There has been a dramatic shift in the focus of glutamate-based therapies away from neurologic disorders such as stroke and traumatic brain injury to the t...
Guardado en:
| Autor Corporativo: | |
|---|---|
| Otros Autores: | |
| Formato: | Electrónico eBook |
| Lenguaje: | English |
| Publicado: |
Basel :
Birkhäuser Basel : Imprint: Birkhäuser,
2010.
|
| Edición: | 1st ed. 2010. |
| Series: | Milestones in Drug Therapy,
|
| Materias: | |
| Acceso en línea: | https://doi.org/10.1007/978-3-0346-0241-9 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Tabla de Contenidos:
- N-Methyl-d-Aspartate (NMDA) Antagonists for the Treatment of Depression
- Ionic Glutamate Modulators in Depression (Zinc, Magnesium)
- Positive Allosteric Modulation of AMPA Receptors: A Novel Potential Antidepressant Therapy
- Glutamatergic Modulators for the Treatment of Major Depressive Disorder: Metabotropic Glutamate Receptors
- Positive Modulation of AMPA Receptors as a Broad-Spectrum Strategy for Treating Neuropsychiatric Disorders
- Activation of Group II Metabotropic Glutamate Receptors (mGluR2 and mGluR3) as a Novel Approach for Treatment of Schizophrenia
- mGluR1 Negative Allosteric Modulators: An Alternative Metabotropic Approach for the Treatment of Schizophrenia
- Metabotropic Glutamate Receptors as Targets for the Treatment of Drug and Alcohol Dependence
- Metabotropic Approaches to Anxiety.